- We have developed a Rametrix® Technology, Inc. algorithm for detection of the molecular fingerprints of bladder cancer in urine (click here for additional information);
- In collaboration with colleagues at Virginia Commonwealth University Massey Cancer Center, we have shown that the molecular fingerprints of bladder cancer in urine are significantly different from molecular fingerprints in urine of patients with bladder infections or prostate disease;
- Our technology may be extremely useful in early detection of bladder cancer in high-risk, asymptomatic individuals (elderly men, smokers, industrial/diesel workers) (we need to do more studies) and in following patients after treatment – without the need for uncomfortable repeat cystoscopies.
